Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

Authors

Bernard Nordlinger

Published

October 11, 2013

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(13)70447-9

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

Authors

Bernard Nordlinger

Published

October 11, 2013

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(13)70447-9

Paper

Paper

Paper

Paper

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

Abstract

Supporters

Journal

Topics

DOI

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

Abstract

Supporters

Journal

Topics

DOI